The lawsuit, spearheaded by the Rosen Law Firm, claims that GeneDx misled shareholders by characterizing the Fabric merger as a catalyst for financial improvement and operational efficiency. While executives publicly touted the potential for reducing costs through optimized algorithms and dry lab processes, the complaint alleges that leadership either knew of or recklessly disregarded fundamental flaws within Fabric that threatened the core business.

These purported omissions and false statements allegedly caused significant investor losses when the actual impact of the acquisition was revealed to the market. The case remains in the preliminary stages, as no class has been certified by the court. Shareholders currently hold the right to retain their own counsel or participate as absent members, meaning their eligibility for potential future recovery is not contingent upon serving as a lead plaintiff in the action.